Objectives: To investigate the antimicrobial resistance and assess the molecular characteristics of b-lactamases (ESBLs, AmpC b-lactamases and carbapenemases) among Enterobacteriaceae isolates that caused intraabdominal infections (IAIs) in patients hospitalized in the Asia-Pacific region during 2008-14.
Introduction b-Lactamase-producing species of the Enterobacteriaceae family are notoriously resistant to penicillin, extended-spectrum cephalosporins and carbapenems, which severely limits the therapeutic options for treating patients with infections caused by resistant pathogens. 1 -3 During the past 10 years, in community settings, there has been a marked increase in isolation rates of MDR Enterobacteriaceae species expressing ESBLs, AmpC b-lactamases or carbapenemases. 2, 4 Asia is a known epicentre of antibacterial drug resistance due to ESBL-producing Enterobacteriaceae species, with CTX-M recognized as the most common b-lactamase. 5 -7 In the last decade, New Delhi metallo-b-lactamase (NDM)-and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae have become endemic on the Indian subcontinent and in China. 2, 6, 7 The prevalence of ESBL-producing and carbapenemase-producing Enterobacteriaceae varies remarkably across the Asia-Pacific region. 7 The Study for Monitoring Antimicrobial Resistance Trends (SMART) has continuously monitored the in vitro activities of antimicrobial agents against Gram-negative aerobic pathogens that cause intra-abdominal infections (IAIs) since 2002. This study investigated the geographical distribution and produced detailed genetic data regarding production of ESBLs, AmpC b-lactamases and carbapenemases in clinical isolates of Enterobacteriaceae obtained from patients with IAIs in the Asia-Pacific region during 2008-14. 
Materials and methods

Study countries and isolates
Thirty-seven medical centres in 12 Asia-Pacific countries/regions participated in the SMART programme during 2008 -14, including Australia (n ¼ 5), the Hong Kong Special Administrative Region of China (n ¼ 2), Japan (n ¼ 3), Kazakhstan (n ¼ 1), Malaysia (n ¼ 2), New Zealand (n ¼ 4), Singapore (n ¼ 2), South Korea (n ¼ 2), Taiwan (n ¼ 8), Thailand (n ¼ 2), the Philippines (n ¼ 2) and Vietnam (n ¼ 4). Consecutive isolates of Enterobacteriaceae cultured from clinical specimens of patients with IAIs were collected. Clinical specimens from urine with significant pyuria, tissues of the urinary tract (ureter, urinary bladder, prostate, urethra) and intra-abdominal sites related to IAIs comprised tissue, fluid or deep wound cultures obtained intraoperatively, and fluid from paracentesis or percutaneous aspiration of abscesses. Duplicate isolates (the same species from the same patient within 30 days from the first positive culture) were excluded. Isolates collected within 48 h of admission to hospitals were presumptively categorized as community-acquired (CA) IAIs, while those collected ≥48 h after admission were categorized as hospitalacquired (HA) IAIs.
Antimicrobial susceptibility testing and molecular detection of ESBLs, AmpC b-lactamases and carbapenemases
Antimicrobial susceptibility testing (MICs of cefoxitin, ceftriaxone, piperacillin/tazobactam, cefepime, ertapenem, imipenem, amikacin, ciprofloxacin and levofloxacin) by the broth microdilution method, quality control testing and molecular analyses (via multiplex PCR) for all Enterobacteriaceae isolates were performed by the central laboratory (International Health Management Associates, Inc., Schaumburg, IL, USA). Antimicrobial susceptibility results were interpreted according to MIC breakpoints recommended by the CLSI in 2015. 8 Multiplex PCR for detection of genes conferring ESBLs, AmpC b-lactamases and carbapenemases was performed for all isolates with ertapenem MIC .0.5 mg/L. Whole genomic DNA of the isolates was extracted using a QIAamp DNA minikit and QIAcube instrument (Qiagen, Valencia, CA, USA) from colonies grown overnight on blood agar plate (Remel, Lenexa, KS, USA). Specific primers to detect ESBL alleles (bla CTX-M , bla TEM , bla SHV , bla VEB , bla GES and bla PER ), plasmid-mediated AmpC genes (bla ACC , bla CMY , bla MOX , bla FOX , bla DHA bla ACT and bla MIR ) and bla SPM , bla GIM , bla KPC , bla VIM , bla NDM , bla IMP and bla OXA genes were used as previously described. 9 
Statistical analysis
The x 2 test was used to evaluate differences in percentages of isolate numbers between two indicated subgroups. Additionally, linear regression analysis was used to analyse the trend of annual rates on various b-lactamases among Enterobacteriaceae isolates. A P value ,0.05 was considered statistically significant; all tests were two-tailed. All analyses were performed with the statistical package SPSS for Windows (version 17.0, SPSS, Chicago, IL, USA).
Results
Isolates harbouring various resistance alleles
During the study period, 2893 isolates with ertapenem MIC .0.5 mg/L were collected. Among these isolates, 2728 harboured b-lactamase genes. The b-lactamase-producing isolates comprised Escherichia coli (n ¼ 1739, 63.7%), K. pneumoniae (n ¼ 714, 26.2%), Enterobacter cloacae (n ¼ 200, 7.3%), Proteus mirabilis (n ¼ 21, 0.8%) and other species. Among the countries submitting .200 isolates, only IAI isolates collected from the Philippines and Vietnam had higher non-susceptible rates to imipenem (17.7% and 10.2%, respectively) than others (average, 7.9%).
Trends of antimicrobial susceptibilities and b-lactamase production
Among the 2728 b-lactamase-producing Enterobacteriaceae isolates, a stepwise and significant increase in annual rates of carbapenemase production (R ¼ 0.793, P ¼ 0.03), rising from 0.07% in 2008 to 1.1% in 2013, was found. Moreover, during 2008-10, IMP-26 enzyme was the predominant carbapenemase. However, the bla NDM-1 allele became the most prevalent carbapenemase-encoding gene among the carbapenemase-producing isolates from 2011 onwards. For non-susceptible rates of antimicrobials evaluated against these IAI isolates, imipenem and amikacin showed the most favourable in vitro activities (8.0% and 9.3%, respectively), followed by ertapenem (20.7%), piperacillin/tazobactam (31.7%) and cefoxitin (36.7%), whereas prominently high non-susceptibilities were noted for levofloxacin (64.0%), ciprofloxacin (72.9%), cefepime (86.3%) and ceftriaxone (99.7%).
Proportions of CA-IAI versus HA-IAI isolates with different ESBL status
There was a significant difference in proportions of CA isolates between ertapenem-susceptible and ertapenem-non-susceptible subgroups of ESBL-positive E. coli isolates (31.7% versus 46.0%, P ¼ 0.011), whereas no such difference was noted for ESBLproducing K. pneumoniae isolates (ertapenem-susceptible versus ertapenem-non-susceptible isolates, 30.9% versus 35.6%, P ¼ 0.307). 
Data on important ESBL and AmpC enzymes among IAI isolates
Geographical distribution of various carbapenemases among IAI isolates
As shown in Table 2 , no carbapenemase-producing Enterobacteriaceae isolates were identified in Hong Kong, South Korea, Kazakhstan, Singapore and New Zealand during this period. Of special note, some IAI bla KPC-2 -, bla NDM-1 -, bla NDM-4 -and bla NDM-5 -harbouring bacteria (including E. coli, K. pneumoniae, E. cloacae and Citrobacter freundii) were isolated in Vietnam during 2010 -14. Likewise, many isolates of KPC-2-, NDM-1-and NDM-7-producing Enterobacteriaceae species have been found in the Philippines since 2011. Furthermore, one IAI bla NDM-1 -harbouring K. pneumoniae isolate was identified in Malaysia in 2013, as well as one in Australia and two in Thailand in 2014. Moreover, 10 bla OXA-48 -harbouring isolates, including E. coli (n¼ 3), K. pneumoniae (n¼ 5) and E. cloacae (n¼ 2), were identified in Vietnam from 2011 to 2014.
Discussion
In this survey, for proven b-lactamase-producing isolates, more than 30% of ESBL-positive isolates of E. coli and K. pneumoniae were obtained from patients with CA-IAIs. Similarly, a significant percentage (36%) of AmpC producers were also CA in origin. In addition, most of the E. cloacae isolates that co-produced carbapenemases (mainly NDM-1) and AmpC were acquired from community settings as well. These findings underscore that Asia is an epicentre of horizontal transfers of high-level resistance alleles between Gram-negative bacteria irrespective of community or nosocomial settings. The plasmids of E. coli are prime disseminators of resistance genes because they are major reservoirs of ISEcp1 and ISCR1, important elements in mobilizing the bla CTX-M -like, bla CMY-2 -like, bla CMY-1 -like and bla DHA-1 -like genes. 3, 10 Compared with the IAI survey by Sheng et al.,
7 CTX-M-14 and CTX-M-15 alleles, prevalent among E. coli and K. pneumoniae in Japan, 11 have been detected among a broader range of species (E. cloacae, Klebsiella oxytoca, Proteus mirabilis) across many Asian countries in our survey. Additionally, the high prevalence of CTX-M-27 among E. coli isolates could be attributed to those submitted by Vietnam (57.1%), consistent with one recent analysis. 12 In contrast to our findings, several studies reported that there were great diversities of AmpC variants among E. coli isolates collected in some Asian countries. 13 In our study, we found that 11.7% (203/1739) of all IAI E. coli isolates produced plasmidmediated AmpC enzymes (mainly CMY-2). The rate was similar to that reported by Oteo et al.
14 Moreover, we also found that the rate of plasmid-mediated AmpC production (17.9%, predominantly DHA-1) was higher among K. pneumoniae than among E. coli isolates (P, 0.001), resembling the rates reported by Yoo et al.
15
Similar to bla CTX-M and many AmpC-encoding alleles, ISs or transposons (ISKpn21, ISAba125; Tn4401; Tn1999 or Tn1999.2) also increase the mobilization potential of the bla NDM-1 , bla KPC-2 and bla OXA-48 alleles in some Enterobacteriaceae species. 16, 17 In this study, we found that bla NDM -positive Enterobacteriaceae species (primarily E. coli, K. pneumoniae and E. cloacae) were predominantly isolated from patients in Vietnam and the Philippines. Gram-negative bacteria harbouring bla NDM alleles in clinical samples were first isolated in Vietnam in 2009 18 and have been identified since 2010 in our study. Owing to the close cultural and economic links between Vietnam and India, it is not surprising that extensive person-to-person exchanges likely resulted in the emergence of bla NDM-1 -harbouring K. pneumoniae strains in Vietnam. 19 In contrast, no other surveys address clinical bla KPC-2 -and bla NDM-1,7 -bearing E. coli, K. pneumoniae or E. cloacae isolates cultured from patients with IAIs hospitalized in the Philippines until now. Similarly, this is the first known study reporting detection of bla OXA-48 -harbouring Enterobacteriaceae isolates from IAI patients in Vietnam.
This study has some limitations. Firstly, as described by Rodríguez-Bañ o et al., 20 the antimicrobial susceptibilities of CA isolates might be complicated by some healthcare factors, not investigated in this study. Secondly, high ertapenem MICs among Enterobacteriaceae spp. might be due to disappearance of important membrane porins and/or development of efflux pumps, which were not characterized in this investigation. Finally, the genetic relatedness and clones of special sequence types (e.g. ST131 E. coli, ST11 K. pneumoniae) of the enrolled isolates were not determined in this study.
In summary, the ESBL variants of CTX-M-14 and CTX-M-15 were prevalent in major Enterobacteriaceae species across all Asia-Pacific countries. The high CA rates among bla CMY-2 -harbouring E. coli and bla DHA-1 -harbouring K. pneumoniae isolates (both ≥38% CA) indicate that these two subsets along with Enterobacter spp. isolates pose enormous challenges to future IAI therapy. In addition, the IAI Enterobacteriaceae isolates collected from some countries (such as Vietnam and the Philippines) showed high levels of antimicrobial resistance. Consequently, there is an imminent need for improving antimicrobial prescription and infection control policies to halt the worsening trend in antimicrobial resistance among Enterobacteriaceae species causing IAIs. 
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